ATE360630T1 - Azabicyclische heterocyclen als modulatoren des cannabinoidrezeptors - Google Patents
Azabicyclische heterocyclen als modulatoren des cannabinoidrezeptorsInfo
- Publication number
- ATE360630T1 ATE360630T1 AT04814952T AT04814952T ATE360630T1 AT E360630 T1 ATE360630 T1 AT E360630T1 AT 04814952 T AT04814952 T AT 04814952T AT 04814952 T AT04814952 T AT 04814952T AT E360630 T1 ATE360630 T1 AT E360630T1
- Authority
- AT
- Austria
- Prior art keywords
- sup
- formula
- modulators
- cannabinoid receptor
- therapeutic agents
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US53145103P | 2003-12-19 | 2003-12-19 | |
US11/016,135 US7378418B2 (en) | 2003-12-19 | 2004-12-17 | Azabicyclic heterocycles as cannabinoid receptor modulators |
Publications (1)
Publication Number | Publication Date |
---|---|
ATE360630T1 true ATE360630T1 (de) | 2007-05-15 |
Family
ID=34703659
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AT04814952T ATE360630T1 (de) | 2003-12-19 | 2004-12-17 | Azabicyclische heterocyclen als modulatoren des cannabinoidrezeptors |
Country Status (20)
Country | Link |
---|---|
US (1) | US7378418B2 (de) |
EP (1) | EP1697370B1 (de) |
JP (1) | JP2007514768A (de) |
AT (1) | ATE360630T1 (de) |
AU (1) | AU2004309365A1 (de) |
BR (1) | BRPI0417771A (de) |
CA (1) | CA2550435A1 (de) |
CY (1) | CY1106674T1 (de) |
DE (1) | DE602004006165T2 (de) |
DK (1) | DK1697370T3 (de) |
ES (1) | ES2282927T3 (de) |
HK (1) | HK1095139A1 (de) |
HR (1) | HRP20070241T3 (de) |
IL (1) | IL176107A0 (de) |
IS (1) | IS8502A (de) |
NO (1) | NO20062704L (de) |
PL (1) | PL1697370T3 (de) |
PT (1) | PT1697370E (de) |
RU (1) | RU2006126122A (de) |
WO (1) | WO2005063761A1 (de) |
Families Citing this family (64)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20100210590A1 (en) * | 1995-09-27 | 2010-08-19 | Northwestern University | Compositions and treatments for seizure-related disorders |
US20030176437A1 (en) | 2001-08-31 | 2003-09-18 | D.M. Watterson | Anti-inflammatory and protein kinase inhibitor compositions and related methods for downregulation of detrimental cellular responses and inhibition of cell death |
ATE452890T1 (de) * | 2003-11-04 | 2010-01-15 | Merck & Co Inc | Substituierte naphthyridinonderivate |
WO2006050359A2 (en) * | 2004-11-02 | 2006-05-11 | Northwestern University | Pyridazine compounds and methods |
BRPI0517947A (pt) | 2004-11-02 | 2008-10-21 | Univ Northwestern | composto de piridazina, composições e métodos |
MX2007012253A (es) * | 2005-04-04 | 2007-12-07 | Univ Pontificia Catolica Chile | Uso de ezetimibe para la prevencion y tratamiento de calculos de colesterol en la via biliar. |
US7632837B2 (en) | 2005-06-17 | 2009-12-15 | Bristol-Myers Squibb Company | Bicyclic heterocycles as cannabinoid-1 receptor modulators |
US7452892B2 (en) | 2005-06-17 | 2008-11-18 | Bristol-Myers Squibb Company | Triazolopyrimidine cannabinoid receptor 1 antagonists |
WO2007080720A1 (ja) * | 2005-12-07 | 2007-07-19 | Sumitomo Chemical Company, Limited | ピリダジン化合物およびその用途 |
WO2007071023A1 (en) * | 2005-12-20 | 2007-06-28 | Merck Frosst Canada Ltd. | Heteroaromatic compounds as inhibitors of stearoyl-coenzyme a delta-9 desaturase |
US20080027087A1 (en) * | 2006-02-21 | 2008-01-31 | Ampla Pharmaceuticals, Inc. | CB1 antagonists and inverse agonists |
WO2007127474A2 (en) * | 2006-04-28 | 2007-11-08 | Northwestern University | Compositions and treatments using pyridazine compounds and cholinesterase inhibitors |
CN101754762A (zh) | 2006-04-28 | 2010-06-23 | 西北大学 | 用于治疗神经炎症性疾病的包含哒嗪化合物的制剂 |
AR061637A1 (es) * | 2006-06-26 | 2008-09-10 | Epix Delaware Inc | Composiciones y metodos de tratamiento de trastornos del snc |
RU2009108280A (ru) | 2006-08-08 | 2010-09-20 | Санофи-Авентис (Fr) | Ариламиноарилалкилзамещенные имидазолидин-2,4-дионы, способы их получения, содержащие эти соединения лекарственные средства и их применение |
EP2051696A2 (de) * | 2006-08-18 | 2009-04-29 | Morton Grove Pharmaceuticals, Inc. | Stabile flüssige levetiracetam-zusammensetzungen und verfahren |
EP2368879B1 (de) * | 2006-11-30 | 2012-11-21 | Dow AgroSciences LLC | 2,5-Disubstituierte Pyridine als Zwischenprodukte für die Herstellung von 2-substituierten 5-(1-Alkylthio)-alkylpyridinen |
EP1974608A1 (de) * | 2007-03-30 | 2008-10-01 | Bayer CropScience AG | Arylpyridazine als Fungizide |
ES2586433T3 (es) * | 2007-04-11 | 2016-10-14 | Omeros Corporation | Composiciones y métodos para la profilaxis y el tratamiento de adicciones |
US20160331729A9 (en) | 2007-04-11 | 2016-11-17 | Omeros Corporation | Compositions and methods for prophylaxis and treatment of addictions |
US11241420B2 (en) | 2007-04-11 | 2022-02-08 | Omeros Corporation | Compositions and methods for prophylaxis and treatment of addictions |
JP5485148B2 (ja) * | 2007-06-21 | 2014-05-07 | カラ セラピューティクス インコーポレイテッド | 置換イミダゾ複素環 |
EP2025674A1 (de) | 2007-08-15 | 2009-02-18 | sanofi-aventis | Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel |
CA2698808A1 (en) | 2007-09-13 | 2009-03-19 | Concert Pharmaceuticals, Inc. | Synthesis of deuterated catechols and benzo[d][1,3] dioxoles and derivatives thereof |
EP2042491A1 (de) * | 2007-09-14 | 2009-04-01 | Bayer CropScience AG | Pyridazine als Fungizide |
GB2456183A (en) * | 2008-01-04 | 2009-07-08 | Gw Pharma Ltd | Anti-psychotic composition comprising cannabinoids and anti-psychotic medicament |
CN101590239B (zh) * | 2008-05-30 | 2013-03-27 | 北京奥萨医药研究中心有限公司 | 含有利尿剂、他汀和叶酸的药物组合物及其用途 |
WO2010003624A2 (en) | 2008-07-09 | 2010-01-14 | Sanofi-Aventis | Heterocyclic compounds, processes for their preparation, medicaments comprising these compounds, and the use thereof |
TW201010977A (en) * | 2008-08-12 | 2010-03-16 | Takeda Pharmaceutical | Amide compound |
WO2010045522A2 (en) * | 2008-10-16 | 2010-04-22 | Metabolous Pharmaceuticals, Inc. | Combination therapies for the treatment of obesity |
WO2010045416A2 (en) * | 2008-10-16 | 2010-04-22 | Metabolous Pharmaceuticals, Inc. | Combination therapies for the treatment of obesity |
US20100113604A1 (en) * | 2008-10-16 | 2010-05-06 | Aronne Louis J | Combination therapies for the treatment of obesity |
US20100113581A1 (en) * | 2008-10-16 | 2010-05-06 | Aronne Louis J | Combination therapies for the treatment of obesity |
WO2010045417A2 (en) * | 2008-10-16 | 2010-04-22 | Metabolous Pharmaceuticals, Inc. | Combination therapies for the treatment of obesity |
WO2010151503A2 (en) * | 2009-06-25 | 2010-12-29 | Metabolous Pharmaceuticals, Inc. | Combination therapies for the treatment of obesity |
WO2010151565A2 (en) * | 2009-06-26 | 2010-12-29 | Metabolous Pharmaceuticals, Inc. | Combination therapies for the treatment of obesity |
US20100331999A1 (en) * | 2009-06-29 | 2010-12-30 | Aronne Louis J | Combination Therapies for the Treatment of Obesity |
US20110015663A1 (en) * | 2009-07-17 | 2011-01-20 | Aronne Louis J | Combination Therapies for the Treatment of Obesity |
WO2011041584A2 (en) | 2009-09-30 | 2011-04-07 | President And Fellows Of Harvard College | Methods for modulation of autophagy through the modulation of autophagy-enhancing gene products |
US20110082407A1 (en) * | 2009-10-01 | 2011-04-07 | Aronne Louis J | Combination Therapies for the Treatment of Obesity |
TW201124078A (en) | 2009-12-22 | 2011-07-16 | Du Pont | Fungicidal 2-(bicyclic aryloxy) carboxamides |
WO2011078360A1 (ja) | 2009-12-24 | 2011-06-30 | 武田薬品工業株式会社 | アミド化合物 |
EP2582709B1 (de) | 2010-06-18 | 2018-01-24 | Sanofi | Azolopyridin-3-on-derivate als inhibitoren von lipasen und phospholipasen |
EP2612669A4 (de) | 2010-08-31 | 2014-05-14 | Snu R&Db Foundation | Verwendung der fötalen neuprogrammierung eines ppar-agonisten |
JP5852666B2 (ja) * | 2010-11-08 | 2016-02-03 | ジヤンセン・フアーマシユーチカルズ・インコーポレーテツド | 1,2,4−トリアゾロ[4,3−a]ピリジン誘導体およびmGluR2受容体のポジティブアロステリックモジュレーターとしてのそれらの使用 |
WO2012087372A1 (en) | 2010-12-22 | 2012-06-28 | E. I. Du Pont De Nemours And Company | Fungicidal 2-(bicyclic aryloxy)carboxamides |
EP2683699B1 (de) | 2011-03-08 | 2015-06-24 | Sanofi | Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung |
EP2683701B1 (de) | 2011-03-08 | 2014-12-24 | Sanofi | Mit benzyl- oder heteromethylengruppen substituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung |
US8895547B2 (en) | 2011-03-08 | 2014-11-25 | Sanofi | Substituted phenyl-oxathiazine derivatives, method for producing them, drugs containing said compounds and the use thereof |
WO2012120054A1 (de) | 2011-03-08 | 2012-09-13 | Sanofi | Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung |
US8901114B2 (en) | 2011-03-08 | 2014-12-02 | Sanofi | Oxathiazine derivatives substituted with carbocycles or heterocycles, method for producing same, drugs containing said compounds, and use thereof |
US8871758B2 (en) | 2011-03-08 | 2014-10-28 | Sanofi | Tetrasubstituted oxathiazine derivatives, method for producing them, their use as medicine and drug containing said derivatives and the use thereof |
WO2012120051A1 (de) | 2011-03-08 | 2012-09-13 | Sanofi | Mit adamantan- oder noradamantan substituierte benzyl-oxathiazinderivate, diese verbindungen enthaltende arzneimittel und deren verwendung |
EP2683702B1 (de) | 2011-03-08 | 2014-12-24 | Sanofi | Neue substituierte phenyl-oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung |
EP2683704B1 (de) | 2011-03-08 | 2014-12-17 | Sanofi | Verzweigte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung |
JP5437525B1 (ja) | 2012-12-28 | 2014-03-12 | 株式会社ナード研究所 | チロシン誘導体およびチロシン誘導体の製造方法 |
RU2707533C2 (ru) | 2013-03-27 | 2019-11-27 | Ф. Хоффманн-Ля Рош Аг | Генетические маркеры для прогнозирования восприимчивости к терапии |
WO2016016157A1 (en) | 2014-07-30 | 2016-02-04 | F. Hoffmann-La Roche Ag | Genetic markers for predicting responsiveness to therapy with hdl-raising or hdl mimicking agent |
US9585867B2 (en) | 2015-08-06 | 2017-03-07 | Charles Everett Ankner | Cannabinod formulation for the sedation of a human or animal |
MY194619A (en) | 2016-06-02 | 2022-12-07 | Abbvie Inc | Glucocorticoid receptor agonist and immunoconjugates thereof |
WO2018237349A1 (en) * | 2017-06-23 | 2018-12-27 | University Of Washington | TYPE 1 METHIONYL-ARNT SYNTHASEASE INHIBITORS AND METHODS OF USE |
CN111417410B (zh) | 2017-12-01 | 2023-06-23 | 艾伯维公司 | 糖皮质激素受体激动剂及其免疫缀合物 |
MX2020013624A (es) * | 2018-06-15 | 2022-08-11 | Pfizer | Agonistas del receptor glp-1 y usos de los mismos. |
KR102503349B1 (ko) | 2019-05-14 | 2023-02-23 | 프로벤션 바이오, 인코포레이티드 | 제1형 당뇨병을 예방하기 위한 방법 및 조성물 |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3994898A (en) | 1975-10-16 | 1976-11-30 | E. R. Squibb & Sons, Inc. | 1,2,4-Triazolo (4,3-b) pyridazin-3-ones |
US4515791A (en) * | 1980-06-03 | 1985-05-07 | American Cyanamid Company | Substituted phenyl-1,2,4-triazolo[2,3-b]pyridazin-3(2H)ones as anti-asthma agents |
JPS61106576A (ja) | 1984-10-31 | 1986-05-24 | Nippon Soda Co Ltd | トリアゾロピリダジン−3−オン誘導体及び製造方法 |
US6610694B1 (en) | 1998-10-06 | 2003-08-26 | Takeda Chemical Industries, Ltd. | Condensed pyridazine compounds, their production and use |
JP2002205992A (ja) | 2000-11-08 | 2002-07-23 | Takeda Chem Ind Ltd | 二環式トリアゾロン誘導体およびそれを含有する除草剤 |
EP1594848A1 (de) | 2003-02-19 | 2005-11-16 | Neurogen Corporation | Arylsäurepyrimidinylmethylamide, -pyridazinylmethylamide undverwandte verbindungen |
-
2004
- 2004-12-17 RU RU2006126122/04A patent/RU2006126122A/ru not_active Application Discontinuation
- 2004-12-17 PT PT04814952T patent/PT1697370E/pt unknown
- 2004-12-17 WO PCT/US2004/042820 patent/WO2005063761A1/en active Application Filing
- 2004-12-17 JP JP2006545558A patent/JP2007514768A/ja not_active Withdrawn
- 2004-12-17 BR BRPI0417771-1A patent/BRPI0417771A/pt not_active IP Right Cessation
- 2004-12-17 DE DE602004006165T patent/DE602004006165T2/de not_active Expired - Fee Related
- 2004-12-17 ES ES04814952T patent/ES2282927T3/es active Active
- 2004-12-17 PL PL04814952T patent/PL1697370T3/pl unknown
- 2004-12-17 EP EP04814952A patent/EP1697370B1/de active Active
- 2004-12-17 CA CA002550435A patent/CA2550435A1/en not_active Abandoned
- 2004-12-17 US US11/016,135 patent/US7378418B2/en active Active
- 2004-12-17 AT AT04814952T patent/ATE360630T1/de not_active IP Right Cessation
- 2004-12-17 AU AU2004309365A patent/AU2004309365A1/en not_active Abandoned
- 2004-12-17 DK DK04814952T patent/DK1697370T3/da active
-
2006
- 2006-06-04 IL IL176107A patent/IL176107A0/en unknown
- 2006-06-08 IS IS8502A patent/IS8502A/xx unknown
- 2006-06-12 NO NO20062704A patent/NO20062704L/no not_active Application Discontinuation
-
2007
- 2007-02-16 HK HK07101919A patent/HK1095139A1/xx not_active IP Right Cessation
- 2007-05-25 HR HR20070241T patent/HRP20070241T3/xx unknown
- 2007-06-21 CY CY20071100832T patent/CY1106674T1/el unknown
Also Published As
Publication number | Publication date |
---|---|
DK1697370T3 (da) | 2007-09-17 |
NO20062704L (no) | 2006-09-05 |
US7378418B2 (en) | 2008-05-27 |
EP1697370B1 (de) | 2007-04-25 |
PT1697370E (pt) | 2007-05-31 |
DE602004006165D1 (de) | 2007-06-06 |
JP2007514768A (ja) | 2007-06-07 |
CY1106674T1 (el) | 2012-05-23 |
HK1095139A1 (en) | 2007-04-27 |
PL1697370T3 (pl) | 2007-09-28 |
EP1697370A1 (de) | 2006-09-06 |
CA2550435A1 (en) | 2005-07-14 |
US20050143381A1 (en) | 2005-06-30 |
BRPI0417771A (pt) | 2007-04-17 |
IL176107A0 (en) | 2006-10-05 |
DE602004006165T2 (de) | 2008-01-17 |
AU2004309365A1 (en) | 2005-07-14 |
HRP20070241T3 (en) | 2007-07-31 |
ES2282927T3 (es) | 2007-10-16 |
RU2006126122A (ru) | 2008-01-27 |
IS8502A (is) | 2006-06-08 |
WO2005063761A1 (en) | 2005-07-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ATE360630T1 (de) | Azabicyclische heterocyclen als modulatoren des cannabinoidrezeptors | |
ATE360631T1 (de) | Azabicyclische heterocyclen als modulatoren des cannabinoidrezeptors | |
TW200726765A (en) | Triazolopyridine cannabinoid receptor 1 antagonists | |
NO20062689L (no) | Azabisykliske heterosykler som modulatorer for kannabinoidreseptorer | |
WO2006044362A3 (en) | N-sulfonylpiperidine cannabinoid receptor 1 antagonists | |
AU2003301020A1 (en) | Isoquinolinone derivatives and their use as therapeutic agents | |
SE9904508D0 (sv) | New compounds | |
NO20076357L (no) | Azabicykliske heterocykler som cannabinoid reseptor modulatorer | |
SE0401345D0 (sv) | Therapeutic compounds: Pyridine as scaffold | |
SE0402762D0 (sv) | Indazole sulphonamide derivatives | |
SE9900961D0 (sv) | Novel compounds | |
SE0401342D0 (sv) | Therapeutic compounds | |
DE602005010744D1 (de) | Piperazinylpyridinderivate als mittel gegen adipositas | |
SE9903997D0 (sv) | New compounds | |
SE0102055D0 (sv) | New Compounds | |
SE0302573D0 (sv) | Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof | |
SE0301320D0 (sv) | Positive modulators of nicotinic acetylcholine receptors | |
SE0302570D0 (sv) | Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof | |
SE9902267D0 (sv) | New compounds | |
SE0302572D0 (sv) | Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof | |
SE0403118D0 (sv) | New compounds 2 | |
ATE554092T1 (de) | Azabicyclische heterocyclen als cannabinoid- rezeptormodulatoren | |
WO2006076598A3 (en) | Bicyclic heterocycles as cannabinoid receptor modulators | |
SE0402763D0 (sv) | Nitro indazole derivatives | |
WO2006076569A3 (en) | Bicyclic heterocycles as cannabinoid receptor modulators |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
UEP | Publication of translation of european patent specification |
Ref document number: 1697370 Country of ref document: EP |
|
REN | Ceased due to non-payment of the annual fee |